Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Abnormal Proliferation02:23

Abnormal Proliferation

4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.9K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.

Cancer research·2026
Same author

Host metabolism can produce many indoles and phenols independently of the microbiome.

Nature metabolism·2026
Same author

Leveraging 13C-Labeling to Assign Molecular Formulas to Unknown Yeast Metabolites.

Journal of the American Society for Mass Spectrometry·2026
Same author

A Liver-Targeted Copper Supplement Reduces Metabolic Dysfunction-Associated Liver Steatosis by Increasing Lipolysis and Fatty Acid Oxidation.

bioRxiv : the preprint server for biology·2026
Same author

Monocyte infiltration induces CNS arginine catabolism to fuel neuroinflammation.

Nature immunology·2026
Same author

Development of CAR T cells Targeting a Surface RNA Binding Protein for the Treatment of Acute Leukemias.

Cancer discovery·2026

相关实验视频

Updated: Sep 8, 2025

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.3K

PAX3-FOXO1驱动可向的细胞状态依赖于Rhabdomyosarcoma的代谢脆弱性

Katrina I Paras1, Julia S Brunner1, Angela M Montero1

  • 1Memorial Sloan Kettering Cancer Center, New York, United States.

Cancer research
|September 5, 2025
PubMed
概括
此摘要是机器生成的。

由PAX3-FOXO1驱动的侵袭性肌肉肉瘤 (RMS) 显示对胺合成的依赖性增加. 针对二叶酸还原酶 (DHFR) 提供了对这些儿童瘤的潜在新疗法.

更多相关视频

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.5K
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

1.9K

相关实验视频

Last Updated: Sep 8, 2025

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.3K
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.5K
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

1.9K

科学领域:

  • 癌症学
  • 分子生物学
  • 生物化学

背景情况:

  • PAX3-FOXO1是激进性肌肉肉瘤 (RMS) 的一个关键驱动因素.
  • 恶性细胞通常表现出改变的代谢途径以支持快速生长.
  • 了解RMS亚型的特定代谢依赖性对于向治疗至关重要.

研究的目的:

  • 研究PAX3-FOXO1驱动的RMS中的代谢变化.
  • 确定与这些代谢变化相关的潜在治疗漏洞.
  • 在PAX3-FOXO1+ RMS中评估向皮里米丁合成的有效性.

主要方法:

  • 在PAX3-FOXO1+RMS细胞中分析基因表达和代谢途径.
  • 通过使用甲醇来评估细胞对二叶酸减少酶 (DHFR) 抑制的敏感性.
  • 用胺核酸进行救援实验.
  • 使用PAX3- FOXO1+和融合负RMS异种移植模型的体内研究.

主要成果:

  • PAX3- FOXO1+ RMS细胞表现出改变的皮里米丁代谢与增加的依赖 de novo合成,包括DHFR.
  • 这些细胞对甲基胺抑制的DHFR敏感,这种敏感性可以通过pyrimidine核酸被挽救.
  • 甲甲酸治疗复制了PAX3- FOXO1沉默的代谢和转录效应.
  • 在PAX3- FOXO1+ RMS外移植患者中,甲甲酸显著减缓了瘤的生长,但在融合阴性RMS患者中却没有.

结论:

  • 在RMS中,PAX3- FOXO1致癌因子会诱导皮里米丁依赖状态.
  • 在PAX3- FOXO1驱动性肌肉瘤中,通过甲基甲胺抑制DHFR是一种有前途的治疗策略.
  • 甲托雷克萨特可以作为对这些侵袭性儿科瘤的治疗方案的宝贵补充剂.